ProMIS Neurosciences Undertakes Reverse Stock Split
ProMIS Neurosciences Inc. (NASDAQ: PMN), a progressive player in the biotechnology sector focused on Alzheimer's disease therapies, is making headlines with the announcement of a one-for-twenty-five reverse stock split. Such a strategic maneuver indicates the company’s efforts to enhance the market value of its shares amidst a demanding financial landscape.
Details of the Stock Split
The reverse stock split will be effective at 12:01 a.m. Eastern Time on November 28, as ProMIS transitions its common shares to a split-adjusted basis. With this adjustment, every 25 existing shares will be consolidated into one new share. This decision is expected to decrease the outstanding Common Shares count from approximately 53.8 million to 2.15 million.
Impact on Shareholders
Shareholders should note that no fractional shares will be issued from this transaction. Instead, those entitled to fractional shares will receive cash equivalently. Furthermore, anyone who holds stock in book-entry or through an intermediary will find these adjustments automatically reflected in their accounts.
Addressing Market Compliance
ProMIS’s reverse stock split comes as a direct response to the company’s need to align with Nasdaq’s Bid Price Rule, which necessitates a minimum closing bid price of $1.00 per share. Following a deficiency notice from Nasdaq, the company is hopeful that this split will not only increase its stock price but also restore compliance with listing requirements.
Future Outlook and Compliance Period
The company is embracing this approach to potentially improve its market position as it has received an extension from Nasdaq, allowing until late December for compliance with market standards. ProMIS believes that restructuring its share price will play a pivotal role in securing its future as an active participant on the Nasdaq Capital Market.
About ProMIS Neurosciences Inc.
ProMIS Neurosciences stands out as a biotechnology firm driven by research aimed at combatting neurodegenerative diseases through innovative antibody and vaccine development. Utilizing its cutting-edge target discovery platform, EpiSelect™, the company strives to identify Disease-Specific Epitopes (DSEs) present on misfolded proteins that are crucial in the pathogenesis of diseases like Alzheimer’s, Parkinson's, and others.
Company Insights and Developments
With offices located in both Cambridge, Massachusetts, and Toronto, Ontario, ProMIS continues to attract attention within the biotech community for its specialized focus. As it navigates through these changes, the company remains committed to advancing its therapeutic solutions aimed at treating debilitating disorders.
Frequently Asked Questions
What is the reason behind the reverse stock split?
The reverse stock split aims to increase the market price of ProMIS’s shares to comply with Nasdaq's Minimum Bid Price Rule.
How will the reverse stock split affect shareholders?
Shareholders will see their shares consolidated; no fractional shares will be issued, and cash will be provided for any fractional entitlements.
What are the expected benefits of this stock adjustment?
This adjustment is expected to enhance share value, ensuring compliance with Nasdaq listing requirements, thereby supporting market confidence.
When will the reverse stock split take effect?
The reverse stock split will take effect at 12:01 a.m. Eastern Time on November 28.
Who can I contact for more information?
For further inquiries, investors can reach out to ProMIS Neurosciences’ Investor Relations via the provided email address.
